Clinical trials: Adenocarcinoma of Rectum
Colorectal Cancer
Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer
RATIONALE: Rectal reconstruction after surgery to treat rectal cancer may help patients keep some of their bowel function. It is not yet known which method of rectal reconstruction is most effective after surgery.
- Trial name
- NCT00238381
- Testing
- 5 cm colon-J-pouch, side-to-end anastomosis, straight coloanal anastomosis
- Where
- 18 sites in Germany, Switzerland
- Volunteers
- 336 people
- Sponsor
- Swiss Cancer Institute
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer
This pilot clinical trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) works in imaging lymph nodes in patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes…
- Conditions
- Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7
- Trial name
- NCT03280277
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002716
- Testing
- dexamethasone, floxuridine, fluorouracil
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 135 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00016952
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- 15 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rectal Carcinoma
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.
- Trial name
- NCT01751516
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
The purpose of this study is to find the number of natural killer (NK) cells from non-HLA matched donors that can be safely infused into patients with cancer. NK cells are a form of lymphocytes that defend against cancer cells.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT02890758
- Testing
- Natural Killer (NK) Cells, ALT803
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brenda Cooper, MD
Colorectal Cancer, Metastatic Cancer
Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Cryosurgery for liver metastases may have fewer side effects and improve recovery. PURPOSE: Phase II trial to study the effectiveness of cryosurgery for patients with unresectable liver metastases from colorectal…
- Trial name
- NCT00002997
- Testing
- cryosurgery
- Where
- 3 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Colorectal Cancer
Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00814619
- Testing
- panitumumab, capecitabine, therapeutic conventional surgery
- Where
- 24 sites in Hungary, Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Rectal Carcinoma
Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
This study evaluates whether images taken using a photon counting detector CT scanner (PCD-CT) can determine the growth of rectal cancer as well as, or better than, MRI for the management of patients with rectal cancer.
- Trial name
- NCT06965166
- Testing
- PCD-CT
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602329
- Testing
- bevacizumab, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Locally Advanced Rectal Carcinoma
Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy
Colorectal cancer (CRC) claims 10% of global cancer-related deaths annually, with rising incidence. Locally advanced rectal cancer (LARC) requires improved diagnostic techniques.
- Trial name
- PREDICT (NCT06304597)
- Testing
- Imfinzi, Opdivo
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
Rectal Cancer, Colon Cancer
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab.
- Conditions
- Rectal Cancer, Colon Cancer, Metastasis, Adenocarcinoma
- Trial name
- NCT01206530
- Testing
- Hydroxychloroquine, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer
Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients with metastatic or…
- Trial name
- NCT00003786
- Testing
- irofulven
- Where
- 9 sites in United States
- Sponsor
- University of Chicago
Colorectal Cancer
Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00625183
- Testing
- selenomethionine, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or…
- Trial name
- NCT00004193
- Testing
- ISIS 2503
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy
Study on the Applicability of CCR Criteria in Rectal Cancer
This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method.
- Conditions
- PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy, Immunotherapy, Complete Response
- Trial name
- NCT06794099
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Carcinoma
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting
The purpose of this study is to assess the safety and efficacy of S-1 and oxaliplatin combined with radiation by Phase I/II study.
- Trial name
- NCT01227239
- Testing
- S-1, Oxaliplatin, Radiation
- Where
- 6 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Japan Clinical Cancer Research Organization
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
This phase II trial studies how well bevacizumab, fluorouracil, leucovorin calcium, and oxaliplatin before surgery works in treating patients with stage II-III rectal cancer.
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer
- Trial name
- NCT01871571
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Southern California
Locally Advanced Rectal Carcinoma
Radiological Markers in Locally Advanced Rectal Cancer
The goal of this observational study is to evaluate the prognostic significance of radiological markers, including the Likert Score derived from diffusion-weighted MRI (DWI), in patients with locally advanced rectal cancer (LARC)…
- Trial name
- LARC (NCT06843655)
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- IRCCS San Raffaele